M. Scaltriti
Molecular Biology · 2006–2021
A researcher in the Science corpus: 8 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 128 citations into it
- Oncology — 81 citations into it
Whom M. Scaltriti trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts M. Scaltriti overall
- N. Iqbal
- P. Roberts
- M. Wieduwilt
- J. Baselga
- N. Iqbal
- S. Swain
- Phatsapong Yingchoncharoen
- F. Danhier
- Hongyu Zhou
Papers from M. Scaltriti's perspective
Ordered by how strongly the researchers M. Scaltriti trusts endorse each paper. Same corpus, a different order for every researcher.
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancer (Nature Reviews. Cancer)
- BRAF mutation predicts sensitivity to MEK inhibition (Nature)
- Molecular portraits of human breast tumours (Nature)
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer (Nature Genetics)
- Integrative genomic profiling of human prostate cancer (Cancer Cell)
- The landscape of cancer genes and mutational processes in breast cancer (Nature)
- Defining the role of mTOR in cancer. (Cancer Cell)
- ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors (Nature Reviews. Cancer)
- Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. (Cell)
- Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. (Journal of Clinical Oncology)
Their papers
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. (2008) — 815 citations
- AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity (2011) — 975 citations
- Targeted drug delivery strategies for precision medicines (2021) — 883 citations
- Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. (2007) — 892 citations
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers (2018) — 851 citations
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers (2018) — 709 citations
- NTRK fusion-positive cancers and TRK inhibitor therapy (2018) — 1,281 citations
- The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy (2006) — 906 citations